SUPERNUS PHARMACEUTICALS, INC. Deferred Revenue (Non-Current)
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Deferred Revenue (Non-Current) of $309.00 thousand as of 2012-12-31, per its 10-K filed 2013-03-15.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent › Deferred Revenue, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2013-03-15
- 2012-12-31: Deferred Revenue, Noncurrent $309.00K.
- 2012-09-30: Deferred Revenue, Noncurrent $381.00K.
- 2012-06-30: Deferred Revenue, Noncurrent $183.00K.
- 2012-03-31: Deferred Revenue, Noncurrent $407.00K.
| Period end | Deferred Revenue, Noncurrent |
|---|---|
| 2012-12-31 | $309.00K 10-K · filed 2013-03-15 |
| 2012-09-30 | $381.00K 10-Q · filed 2012-11-02 |
| 2012-06-30 | $183.00K 10-Q · filed 2012-08-13 |
| 2012-03-31 | $407.00K 10-Q · filed 2012-06-08 |
| 2011-12-31 | $465.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |